Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
about
Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Comparative genomics allowed the identification of drug targets against human fungal pathogens.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsSelf-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsCharacterization of a Polyethylene Glycol-Amphotericin B Conjugate Loaded with Free AMB for Improved Antifungal Efficacy.Liposomal amphotericin B as a treatment for human leishmaniasisPharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisNanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potencyAccelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.Comparison between liposomal formulations of amphotericin B.Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles.Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases
P2860
Q26740363-6FD234DB-4575-4D68-B7FC-09C7E37F66D7Q33805404-E8659C9E-E036-4513-B4CA-E378D206240EQ34108585-39D8C53C-8489-4A85-9B68-2D5623CBF6E3Q35168703-1B916C9F-3BB1-4980-A0EF-E65C46C3CFD7Q35666612-9BFF7652-3CF2-444A-B525-F77AC359135BQ35967724-F963ECAC-7C8F-4621-A668-BCB49ECDD2DCQ36456032-3B9D0F22-A85C-4907-A032-BA5E31E75213Q36757621-020FFB4B-BB7E-47A7-81A4-9C4813AE1420Q37401889-F9FC4BF2-B722-4F7E-A294-D69CAA349D39Q38342306-8315EE55-12E5-4780-B99B-FBAA4DA70F95Q38696930-07671D57-AB9F-42E5-986C-E4E66B422461Q40166247-440BACD3-CBB7-495A-AFB0-681FA88033CDQ40222438-15830EBB-B90D-45DC-8728-AE10BC244F3CQ41570433-0C0E3403-AE0C-4A3F-8CF8-F593BCFF5DBBQ50043447-F7C96DD3-0B74-4412-95F0-93085E98399EQ57347954-DA29893E-0AAC-462F-83D6-FFB269E27D11
P2860
Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Comparison of the physicochemi ...... somal amphotericin B products.
@ast
Comparison of the physicochemi ...... somal amphotericin B products.
@en
type
label
Comparison of the physicochemi ...... somal amphotericin B products.
@ast
Comparison of the physicochemi ...... somal amphotericin B products.
@en
prefLabel
Comparison of the physicochemi ...... somal amphotericin B products.
@ast
Comparison of the physicochemi ...... somal amphotericin B products.
@en
P2093
P2860
P356
P1476
Comparison of the physicochemi ...... osomal amphotericin B products
@en
P2093
Gerard M Jensen
Jill P Adler-Moore
Jon A Olson
Julie Schwartz
Richard T Proffitt
P2860
P304
P356
10.1128/AAC.00870-07
P407
P577
2007-10-29T00:00:00Z